Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies

被引:91
作者
Heslop, James A. [1 ]
Hammond, Thomas G. [4 ]
Santeramo, Ilaria [2 ]
Piella, Agnes Tort [1 ]
Hopp, Isabel [2 ]
Zhou, Jing [2 ]
Baty, Roua [3 ]
Graziano, Enrique I. [5 ]
Marco, Bernabe Proto [5 ]
Caron, Alexis [6 ]
Skold, Patrik [7 ]
Andrews, Peter W. [8 ]
Baxter, Melissa A. [9 ]
Hay, David C. [10 ]
Hamdam, Junnat [11 ]
Sharpe, Michaela E. [12 ]
Patel, Sara [13 ]
Jones, David R. [14 ]
Reinhardt, Jens [15 ]
Danen, Erik H. J. [16 ]
Ben-David, Uri [17 ]
Stacey, Glyn [18 ]
Bjorquist, Petter [19 ]
Piner, Jacqueline [20 ]
Mills, John [21 ]
Rowe, Cliff [22 ]
Pellegrini, Giovanni [23 ]
Sethu, Swaminathan [24 ,25 ]
Antoine, Daniel J. [1 ]
Cross, Michael J. [1 ]
Murray, Patricia [2 ]
Williams, Dominic P. [26 ]
Kitteringham, Neil R. [1 ]
Goldring, Chris E. P. [1 ,27 ]
Park, B. Kevin [1 ]
机构
[1] Univ Liverpool, Med Res Council, Ctr Drug Safety Sci, Div Mol & Clin Pharmacol, Liverpool, Merseyside L69 3GE, England
[2] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside L69 3GE, England
[3] Univ Liverpool, Inst Integrat Biol, Liverpool, Merseyside L69 3GE, England
[4] Univ Basel, Dept Pharmaceut Sci Pharmazentrum, Div Mol & Syst Toxicol, Basel, Switzerland
[5] Labs Almirall SA Laurea Miro, Sant Feliu de Llobregat, Spain
[6] SANOFI Res & Dev Disposit Safety & Anim Res, Alfortville, France
[7] Uppsala Univ, Uppsala Biomed Ctr BMC, Uppsala, Sweden
[8] Univ Sheffield, Dept Biomed Sci, Ctr Stem Cell Biol, Sheffield S10 2TN, S Yorkshire, England
[9] Univ Manchester, Fac Human & Med Sci, Sch Biomed, Dev & Regenerat Biomed, Manchester, Lancs, England
[10] Univ Edinburgh, Ctr Regenerat Med, MRC, Edinburgh, Midlothian, Scotland
[11] Univ Dusseldorf, Dept Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany
[12] OakMore Solut Ltd, Faversham, England
[13] ReNeuron Ltd, Guildford, Surrey, England
[14] Med & Healthcare Prod Regulatory Agcy, London, England
[15] Paul Ehrlich Inst, Langen, Germany
[16] Leiden Acad, Ctr Drug Res Toxicol, Fac Sci, Leiden, Netherlands
[17] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, Stem Cell Unit, IL-91904 Jerusalem, Israel
[18] UK Stem Cell Bank, Natl Inst Biol Stand & Control, Med & Healthcare Prod Regulatory Agcy, Potters Bar, Herts, England
[19] Cellectis AB, Gothenburg, Sweden
[20] GSK, David Jack Ctr Res & Dev, Ware, Herts, England
[21] AstraZeneca, Personalised Healthcare & Biomarkers, Macclesfield, Cheshire, England
[22] CN Bio Innovat Ltd, Ctr Innovat & Enterprise, Begbroke, England
[23] Univ Zurich, Inst Vet Pathol, Zurich, Switzerland
[24] VIT Univ, Sch Bio Sci &Technol, Vellore, Tamil Nadu, India
[25] VIT Univ, Ctr Biomat Sci &Technol, Vellore, Tamil Nadu, India
[26] AstraZeneca, Drug Safety & Metab, Translat Safety, Cambridge, England
[27] Innovat Med Initiat SafeSciMET, Brussels, Belgium
基金
英国医学研究理事会;
关键词
Adult stem cells; Autologous stem cell transplantation; Cellular therapy; Stem cell expansion; In vivo tracking; Pluripotent stem cells; Stem cell transplantation; Stem cell; VERSUS-HOST-DISEASE; SPINAL-CORD-INJURY; REPORTER GENE-EXPRESSION; THYMIDINE KINASE HSV1-TK; INSULIN-PRODUCING CELLS; IN-VIVO; INDUCED PLURIPOTENT; CHROMOSOMAL-ABERRATIONS; MYOCARDIAL-INFARCTION; STROMAL CELLS;
D O I
10.5966/sctm.2014-0110
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The field of stem cell therapeutics is moving ever closer to widespread application in the clinic. However, despite the undoubted potential held by these therapies, the balance between risk and benefit remains difficult to predict. As in any new field, a lack of previous application in man and gaps in the underlying science mean that regulators and investigators continue to look for a balance between minimizing potential risk and ensuring therapies are not needlessly kept from patients. Here, we attempt to identify the important safety issues, assessing the current advances in scientific knowledge and how they may translate to clinical therapeutic strategies in the identification and management of these risks. We also investigate the tools and techniques currently available to researchers during preclinical and clinical development of stem cell products, their utility and limitations, and how these tools may be strategically used in the development of these therapies. We conclude that ensuring safety through cutting-edge science and robust assays, coupled with regular and open discussions between regulators and academic/industrial investigators, is likely to prove the most fruitful route to ensuring the safest possible development of new products.
引用
收藏
页码:389 / 400
页数:12
相关论文
共 176 条
[1]   A xenograft line of human teratocarcinoma established by serial transplantation in severe combined immunodeficient (SCID) mice [J].
Abe, Y ;
Oshika, Y ;
Ohnishi, Y ;
Suto, R ;
Tokunaga, T ;
Yamazaki, H ;
Kijima, H ;
Hiraoka, N ;
Ueyama, Y ;
Tamaoki, N ;
Nakamura, M .
APMIS, 1997, 105 (04) :283-289
[2]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[3]   Clinical Cell Therapy Imaging Using a Perfluorocarbon Tracer and Fluorine-19 MRI [J].
Ahrens, Eric T. ;
Helfer, Brooke M. ;
O'Hanlon, Charles F. ;
Schirda, Claudiu .
MAGNETIC RESONANCE IN MEDICINE, 2014, 72 (06) :1696-+
[4]   In vivo MRI cell tracking using perfluorocarbon probes and fluorine-19 detection [J].
Ahrens, Eric T. ;
Zhong, Jia .
NMR IN BIOMEDICINE, 2013, 26 (07) :860-871
[5]   Geron gets green light for human trial of ES cell-derived product [J].
Alper, Joe .
NATURE BIOTECHNOLOGY, 2009, 27 (03) :213-214
[6]   Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient [J].
Amariglio, Ninette ;
Hirshberg, Abraham ;
Scheithauer, Bernd W. ;
Cohen, Yoram ;
Loewenthal, Ron ;
Trakhtenbrot, Luba ;
Paz, Nurit ;
Koren-Michowitz, Maya ;
Waldman, Dalia ;
Leider-Trejo, Leonor ;
Toren, Amos ;
Constantini, Shlomi ;
Rechavi, Gideon .
PLOS MEDICINE, 2009, 6 (02) :221-231
[7]   Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage [J].
Amps, Katherine ;
Andrews, Peter W. ;
Anyfantis, George ;
Armstrong, Lyle ;
Avery, Stuart ;
Baharvand, Hossein ;
Baker, Julie ;
Baker, Duncan ;
Munoz, Maria B. ;
Beil, Stephen ;
Benvenisty, Nissim ;
Ben-Yosef, Dalit ;
Biancotti, Juan-Carlos ;
Bosman, Alexis ;
Brena, Romulo Martin ;
Brison, Daniel ;
Caisander, Gunilla ;
Camarasa, Maria V. ;
Chen, Jieming ;
Chiao, Eric ;
Choi, Young Min ;
Choo, Andre B. H. ;
Collins, Daniel ;
Colman, Alan ;
Crook, Jeremy M. ;
Daley, George Q. ;
Dalton, Anne ;
De Sousa, Paul A. ;
Denning, Chris ;
Downie, Janet ;
Dvorak, Petr ;
Montgomery, Karen D. ;
Feki, Anis ;
Ford, Angela ;
Fox, Victoria ;
Fraga, Ana M. ;
Frumkin, Tzvia ;
Ge, Lin ;
Gokhale, Paul J. ;
Golan-Lev, Tamar ;
Gourabi, Hamid ;
Gropp, Michal ;
Lu Guangxiu ;
Hampl, Ales ;
Harron, Katie ;
Healy, Lyn ;
Herath, Wishva ;
Holm, Frida ;
Hovatta, Outi ;
Hyllner, Johan .
NATURE BIOTECHNOLOGY, 2011, 29 (12) :1132-U113
[8]   Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: Opposite sides of the same coin [J].
Andrews, PW ;
Matin, MM ;
Bahrami, AR ;
Damjanov, I ;
Gokhale, P ;
Draper, JS .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2005, 33 :1526-1530
[9]  
[Anonymous], 2014, NAT MED, V20, P226
[10]   Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells [J].
Araki, Ryoko ;
Uda, Masahiro ;
Hoki, Yuko ;
Sunayama, Misato ;
Nakamura, Miki ;
Ando, Shunsuke ;
Sugiura, Mayumi ;
Ideno, Hisashi ;
Shimada, Akemi ;
Nifuji, Akira ;
Abe, Masumi .
NATURE, 2013, 494 (7435) :100-104